CRISPR Therapeutics AG
NASDAQ:CRSP

Watchlist Manager
CRISPR Therapeutics AG Logo
CRISPR Therapeutics AG
NASDAQ:CRSP
Watchlist
Price: 56.66 USD -3.97% Market Closed
Market Cap: 4.9B USD
Have any thoughts about
CRISPR Therapeutics AG?
Write Note

Wall Street
Price Targets

CRSP Price Targets Summary
CRISPR Therapeutics AG

Wall Street analysts forecast CRSP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CRSP is 81.69 USD with a low forecast of 32.32 USD and a high forecast of 281.4 USD.

Lowest
Price Target
32.32 USD
43% Downside
Average
Price Target
81.69 USD
44% Upside
Highest
Price Target
281.4 USD
397% Upside
CRISPR Therapeutics AG Competitors:
Price Targets
OCX
OncoCyte Corp
75% Upside
4599
StemRIM Inc
134% Upside
LGND
Ligand Pharmaceuticals Inc
21% Upside
XGN
Exagen Inc
13% Upside
AUPH
Aurinia Pharmaceuticals Inc
16% Upside
ITOS
Iteos Therapeutics Inc
17% Upside
PLUR
Pluri Inc
126% Upside
KRYS
Krystal Biotech Inc
41% Upside

Revenue
Forecast

Revenue Estimate
CRISPR Therapeutics AG

For the last 8 years the compound annual growth rate for CRISPR Therapeutics AG's revenue is 28%. The projected CAGR for the next 3 years is 122%.

28%
Past Growth
122%
Estimated Growth
Estimates Accuracy
13%
Average Beat

Operating Income
Forecast

Operating Income Estimate
CRISPR Therapeutics AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Net Income
Forecast

Net Income Estimate
CRISPR Therapeutics AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-31%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CRSP's stock price target?
Price Target
81.69 USD

According to Wall Street analysts, the average 1-year price target for CRSP is 81.69 USD with a low forecast of 32.32 USD and a high forecast of 281.4 USD.

What is CRISPR Therapeutics AG's Revenue forecast?
Projected CAGR
122%

For the last 8 years the compound annual growth rate for CRISPR Therapeutics AG's revenue is 28%. The projected CAGR for the next 3 years is 122%.

Back to Top